Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761508 | 0.93 | MAPK8 (0.55) | HDAC1HDAC3HDAC2HDAC6HCAR3 | |
| SCHEMBL30423180 | 0.89 | HDAC1 (0.52) | HDAC1HDAC3HDAC2HDAC6MAPK8 | |
| SCHEMBL13736219 | 0.89 | HDAC3 (0.71) | HDAC1HDAC3HDAC2HDAC6MAPK8 | |
| SCHEMBL13735184 | 0.88 | MAPK8 (0.60) | HDAC1HDAC3HDAC2HDAC6MAPK8 | |
| SCHEMBL13735187 | 0.88 | MAPK8 (0.60) | HDAC1HDAC3HDAC2HDAC6MAPK8 | |
| SCHEMBL13737141 | 0.84 | HDAC3 (0.44) | HDAC1HDAC3HDAC2HDAC6MAPK8 | |
| SCHEMBL13737142 | 0.84 | HDAC3 (0.44) | HDAC1HDAC3HDAC2HDAC6MAPK8 | |
| SCHEMBL185452 | 0.83 | HCAR3 (0.64) | HDAC1HDAC3HDAC2HDAC6HCAR3 | |
| SCHEMBL13733794 | 0.82 | MAPK8 (0.58) | HDAC1HDAC3HDAC2HDAC6MAPK8 | |
| SCHEMBL16047037 | 0.81 | HCAR3 (0.62) | HDAC1HDAC3HDAC2HDAC6HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029987-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | HDAC1 165/4885HDAC3 196/4885HDAC2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.